KDR and hepatocellular carcinoma: Bevacizumab, a monoclonal antibody against VEGF-A, is thought to primarily target VEGFA-VEGFR2 signaling, and we hypothesized that bevacizumab would be more effective if VEGFR2 was expressed in HCC.